Phaseline

Targets › FGF19

FGF19 (Fibroblast growth factor 19): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 3 Phase 1, 2 Phase 2; Oncology, Other; next expected readout Jun 2027.

Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. (UniProt, O95750)

Open in Phaseline: the race on FGF19, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Abbisko TherapeuticsABSK-011 Capsules
FGF19 inhibitor
FGF19Phase 2Hepatocellular Carcinoma (HCC); Healthy Participants; Advanced Liver Cancer; HCC - Hepatocellular CarcinomaJun 2027
Huahui HealthHH-009
FGF19 antagonist
FGF19Phase 1Advanced or Unresectable Hepatocellular Carcinoma (HCC)Oct 2028

Conditions

Hepatocellular Carcinoma (HCC) (1) Healthy Participants (1) Advanced Liver Cancer (1) HCC - Hepatocellular Carcinoma (1) Advanced or Unresectable Hepatocellular Carcinoma (HCC) (1)

Modalities

small molecule (2)

Companies

Abbisko Therapeutics (1) Huahui Health (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.